{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T11:32:16Z","timestamp":1791804736626,"version":"4.3.4"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2015,7,23]],"date-time":"2015-07-23T00:00:00Z","timestamp":1437609600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1007\/s11912-015-0465-x","type":"journal-article","created":{"date-parts":[[2015,7,22]],"date-time":"2015-07-22T05:52:33Z","timestamp":1437544353000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["High-Dose Chemotherapy and Autologous Stem Cell Transplant in Older Patients with Lymphoma"],"prefix":"10.1007","volume":"17","author":[{"given":"Oscar B.","family":"Lahoud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig S.","family":"Sauter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Hamlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parastoo Bahrami","family":"Dahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,7,23]]},"reference":[{"key":"465_CR1","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1200\/JCO.2008.20.8983","volume":"27","author":"BD Smith","year":"2009","unstructured":"Smith BD, Smith GL, Hurria A, et al. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol. 2009;27:2758\u201365.","journal-title":"J Clin Oncol"},{"key":"465_CR2","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1182\/blood.V14.5.503.503","volume":"14","author":"FW Mc","year":"1959","unstructured":"Mc FW, Granville NB, Dameshek W. Autologous bone marrow infusion as an adjunct in therapy of malignant disease. Blood. 1959;14:503\u201321.","journal-title":"Blood"},{"key":"465_CR3","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(61)91720-2","volume":"1","author":"P Clifford","year":"1961","unstructured":"Clifford P, Clift RA, Duff JK. Nitrogen-mustard therapy combined with autologous marrow infusion. Lancet. 1961;1:687\u201390.","journal-title":"Lancet"},{"key":"465_CR4","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/bjc.1962.46","volume":"16","author":"DE Pegg","year":"1962","unstructured":"Pegg DE. A quantitative study of bone marrow grafting: implications for human bone marrow infusion. Br J Cancer. 1962;16:400\u201316.","journal-title":"Br J Cancer"},{"key":"465_CR5","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/j.1537-2995.1962.tb00218.x","volume":"2","author":"NB Kurnick","year":"1962","unstructured":"Kurnick NB. Autologous and isologous bone marrow storage and infusion in the treatment of myelo-suppresson. Transfusion. 1962;2:178\u201387.","journal-title":"Transfusion"},{"key":"465_CR6","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1182\/blood.V52.1.85.85","volume":"52","author":"FR Appelbaum","year":"1978","unstructured":"Appelbaum FR, Herzig GP, Ziegler JL, et al. Successful engraftment of cryopreserved autologous bone marrow in patients with malignant lymphoma. Blood. 1978;52:85\u201395.","journal-title":"Blood"},{"key":"465_CR7","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1002\/1097-0142(197803)41:3<1059::AID-CNCR2820410339>3.0.CO;2-N","volume":"41","author":"FR Appelbaum","year":"1978","unstructured":"Appelbaum FR, Deisseroth AB, Graw Jr RG, et al. Prolonged complete remission following high dose chemotherapy of Burkitt\u2019s lymphoma in relapse. Cancer. 1978;41:1059\u201363.","journal-title":"Cancer"},{"key":"465_CR8","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1182\/blood.V73.8.2086.2086","volume":"73","author":"GL Phillips","year":"1989","unstructured":"Phillips GL, Wolff SN, Herzig RH, et al. Treatment of progressive Hodgkin\u2019s disease with intensive chemoradiotherapy and autologous bone marrow transplantation. Blood. 1989;73:2086\u201392.","journal-title":"Blood"},{"key":"465_CR9","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/0277-5379(85)90089-6","volume":"21","author":"AM Carella","year":"1985","unstructured":"Carella AM, Santini G, Santoro A, et al. Massive chemotherapy with non-frozen autologous bone marrow transplantation in 13 cases of refractory Hodgkin\u2019s disease. Eur J Cancer Clin Oncol. 1985;21:607\u201313.","journal-title":"Eur J Cancer Clin Oncol"},{"key":"465_CR10","doi-asserted-by":"crossref","first-page":"163","DOI":"10.7326\/0003-4819-104-2-163","volume":"104","author":"S Jagannath","year":"1986","unstructured":"Jagannath S, Dicke KA, Armitage JO, et al. High-dose cyclophosphamide, carmustine, and etoposide and autologous bone marrow transplantation for relapsed Hodgkin\u2019s disease. Ann Intern Med. 1986;104:163\u20138.","journal-title":"Ann Intern Med"},{"key":"465_CR11","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/0140-6736(93)92411-L","volume":"341","author":"DC Linch","year":"1993","unstructured":"Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin\u2019s disease: results of a BNLI randomised trial. Lancet. 1993;341:1051\u20134.","journal-title":"Lancet"},{"key":"465_CR12","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","volume":"359","author":"N Schmitz","year":"2002","unstructured":"Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin\u2019s disease: a randomised trial. Lancet. 2002;359:2065\u201371.","journal-title":"Lancet"},{"key":"465_CR13","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1038\/sj.bmt.1705371","volume":"37","author":"FK Buadi","year":"2006","unstructured":"Buadi FK, Micallef IN, Ansell SM, et al. Autologous hematopoietic stem cell transplantation for older patients with relapsed non-Hodgkin\u2019s lymphoma. Bone Marrow Transplant. 2006;37:1017\u201322.","journal-title":"Bone Marrow Transplant"},{"key":"465_CR14","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.bbmt.2008.09.008","volume":"14","author":"HM Lazarus","year":"2008","unstructured":"Lazarus HM, Carreras J, Boudreau C, et al. Influence of age and histology on outcome in adult non-Hodgkin lymphoma patients undergoing autologous hematopoietic cell transplantation (HCT): a report from the Center For International Blood & Marrow Transplant Research (CIBMTR). Biol Blood Marrow Transplant. 2008;14:1323\u201333.","journal-title":"Biol Blood Marrow Transplant"},{"key":"465_CR15","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","volume":"333","author":"T Philip","year":"1995","unstructured":"Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin\u2019s lymphoma. N Engl J Med. 1995;333:1540\u20135.","journal-title":"N Engl J Med"},{"key":"465_CR16","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1200\/JCO.1998.16.12.3803","volume":"16","author":"IF Khouri","year":"1998","unstructured":"Khouri IF, Romaguera J, Kantarjian H, et al. Hyper-CVAD and high-dose methotrexate\/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol. 1998;16:3803\u20139.","journal-title":"J Clin Oncol"},{"key":"465_CR17","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1002\/cncr.21313","volume":"104","author":"C Thieblemont","year":"2005","unstructured":"Thieblemont C, Antal D, Lacotte-Thierry L, et al. Chemotherapy with rituximab followed by high-dose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma. Cancer. 2005;104:1434\u201341.","journal-title":"Cancer"},{"key":"465_CR18","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00277-006-0193-2","volume":"86","author":"DS Ritchie","year":"2007","unstructured":"Ritchie DS, Seymour JF, Grigg AP, et al. The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma. Ann Hematol. 2007;86:101\u20135.","journal-title":"Ann Hematol"},{"key":"465_CR19","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1182\/blood-2011-07-369629","volume":"119","author":"AS LaCasce","year":"2012","unstructured":"LaCasce AS, Vandergrift JL, Rodriguez MA, et al. Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database. Blood. 2012;119:2093\u20139.","journal-title":"Blood"},{"key":"465_CR20","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","volume":"112","author":"CH Geisler","year":"2008","unstructured":"Geisler CH, Kolstad A, Laurell A, et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood. 2008;112:2687\u201393.","journal-title":"Blood"},{"key":"465_CR21","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2141.2012.09174.x","volume":"158","author":"CH Geisler","year":"2012","unstructured":"Geisler CH, Kolstad A, Laurell A, et al. Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC\u2009+\u2009autologous stem-cell support: still very long survival but late relapses do occur. Br J Haematol. 2012;158:355\u201362.","journal-title":"Br J Haematol"},{"key":"465_CR22","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","volume":"105","author":"M Dreyling","year":"2005","unstructured":"Dreyling M, Lenz G, Hoster E, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood. 2005;105:2677\u201384.","journal-title":"Blood"},{"key":"465_CR23","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","volume":"30","author":"F d\u2019Amore","year":"2012","unstructured":"d\u2019Amore F, Relander T, Lauritzsen GF, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol. 2012;30:3093\u20139.","journal-title":"J Clin Oncol"},{"key":"465_CR24","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/sj.bmt.1705752","volume":"40","author":"S Feyler","year":"2007","unstructured":"Feyler S, Prince HM, Pearce R, et al. The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study. Bone Marrow Transplant. 2007;40:443\u201350.","journal-title":"Bone Marrow Transplant"},{"key":"465_CR25","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/sj.bmt.1704367","volume":"33","author":"E Jantunen","year":"2004","unstructured":"Jantunen E, Wiklund T, Juvonen E, et al. Autologous stem cell transplantation in adult patients with peripheral T-cell lymphoma: a nation-wide survey. Bone Marrow Transplant. 2004;33:405\u201310.","journal-title":"Bone Marrow Transplant"},{"key":"465_CR26","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1093\/annonc\/mdl466","volume":"18","author":"J Rodriguez","year":"2007","unstructured":"Rodriguez J, Conde E, Gutierrez A, et al. The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience. Ann Oncol. 2007;18:652\u20137.","journal-title":"Ann Oncol"},{"key":"465_CR27","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.bbmt.2013.04.027","volume":"19","author":"PL McCarthy Jr","year":"2013","unstructured":"McCarthy Jr PL, Hahn T, Hassebroek A, et al. Trends in use of and survival after autologous hematopoietic cell transplantation in North America, 1995\u20132005: significant improvement in survival for lymphoma and myeloma during a period of increasing recipient age. Biol Blood Marrow Transplant. 2013;19:1116\u201323.","journal-title":"Biol Blood Marrow Transplant"},{"key":"465_CR28","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.critrevonc.2008.01.013","volume":"67","author":"JF Piccirillo","year":"2008","unstructured":"Piccirillo JF, Vlahiotis A, Barrett LB, et al. The changing prevalence of comorbidity across the age spectrum. Crit Rev Oncol Hematol. 2008;67:124\u201332.","journal-title":"Crit Rev Oncol Hematol"},{"key":"465_CR29","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/sj.bmt.1700838","volume":"20","author":"P Brice","year":"1997","unstructured":"Brice P, Bouabdallah R, Moreau P, et al. Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin\u2019s disease: analysis of 280 patients from the French registry. Societe Francaise de Greffe de Moelle. Bone Marrow Transplant. 1997;20:21\u20136.","journal-title":"Bone Marrow Transplant"},{"key":"465_CR30","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood.V97.3.616","volume":"97","author":"CH Moskowitz","year":"2001","unstructured":"Moskowitz CH, Nimer SD, Zelenetz AD, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood. 2001;97:616\u201323.","journal-title":"Blood"},{"issue":"Suppl 1","key":"465_CR31","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1093\/annonc\/13.S1.128","volume":"13","author":"A Sureda","year":"2002","unstructured":"Sureda A, Schmitz N. Role of allogeneic stem cell transplantation in relapsed or refractory Hodgkin\u2019s disease. Ann Oncol. 2002;13 Suppl 1:128\u201332.","journal-title":"Ann Oncol"},{"key":"465_CR32","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1002\/cncr.22714","volume":"109","author":"E Jabbour","year":"2007","unstructured":"Jabbour E, Hosing C, Ayers G, et al. Pretransplant positive positron emission tomography\/gallium scans predict poor outcome in patients with recurrent\/refractory Hodgkin lymphoma. Cancer. 2007;109:2481\u20139.","journal-title":"Cancer"},{"key":"465_CR33","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/j.bbmt.2011.04.011","volume":"17","author":"JP Smeltzer","year":"2011","unstructured":"Smeltzer JP, Cashen AF, Zhang Q, et al. Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation. Biol Blood Marrow Transplant. 2011;17:1646\u201352.","journal-title":"Biol Blood Marrow Transplant"},{"key":"465_CR34","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1182\/blood-2011-10-388058","volume":"119","author":"CH Moskowitz","year":"2012","unstructured":"Moskowitz CH, Matasar MJ, Zelenetz AD, et al. Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood. 2012;119:1665\u201370.","journal-title":"Blood"},{"key":"465_CR35","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1002\/cncr.23861","volume":"113","author":"E Derenzini","year":"2008","unstructured":"Derenzini E, Musuraca G, Fanti S, et al. Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma. Cancer. 2008;113:2496\u2013503.","journal-title":"Cancer"},{"key":"465_CR36","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1365-2141.2010.08162.x","volume":"150","author":"M Dickinson","year":"2010","unstructured":"Dickinson M, Hoyt R, Roberts AW, et al. Improved survival for relapsed diffuse large B cell lymphoma is predicted by a negative pre-transplant FDG-PET scan following salvage chemotherapy. Br J Haematol. 2010;150:39\u201345.","journal-title":"Br J Haematol"},{"key":"465_CR37","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","volume":"329","author":"MA Shipp","year":"1993","unstructured":"Shipp MA, Harrington DP, Anderson JR, et al. A predictive model for aggressive non-Hodgkin\u2019s lymphoma. The International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329:987\u201394.","journal-title":"N Engl J Med"},{"key":"465_CR38","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","volume":"104","author":"P Solal-Celigny","year":"2004","unstructured":"Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004;104:1258\u201365.","journal-title":"Blood"},{"key":"465_CR39","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","volume":"111","author":"E Hoster","year":"2008","unstructured":"Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008;111:558\u201365.","journal-title":"Blood"},{"key":"465_CR40","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","volume":"109","author":"LH Sehn","year":"2007","unstructured":"Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109:1857\u201361.","journal-title":"Blood"},{"key":"465_CR41","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1182\/blood-2013-09-524108","volume":"123","author":"Z Zhou","year":"2014","unstructured":"Zhou Z, Sehn LH, Rademaker AW, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014;123:837\u201342.","journal-title":"Blood"},{"key":"465_CR42","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/j.1365-2141.2010.08331.x","volume":"151","author":"RH Advani","year":"2010","unstructured":"Advani RH, Chen H, Habermann TM, et al. Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E-IPI). Br J Haematol. 2010;151:143\u201351.","journal-title":"Br J Haematol"},{"key":"465_CR43","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1182\/blood-2002-12-3837","volume":"102","author":"PA Hamlin","year":"2003","unstructured":"Hamlin PA, Zelenetz AD, Kewalramani T, et al. Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood. 2003;102:1989\u201396.","journal-title":"Blood"},{"key":"465_CR44","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","volume":"28","author":"C Gisselbrecht","year":"2010","unstructured":"Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28:4184\u201390.","journal-title":"J Clin Oncol"},{"key":"465_CR45","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912\u20139.","journal-title":"Blood"},{"key":"465_CR46","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1200\/JCO.2013.53.8157","volume":"32","author":"ML Sorror","year":"2014","unstructured":"Sorror ML, Storb RF, Sandmaier BM, et al. Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation. J Clin Oncol. 2014;32:3249\u201356.","journal-title":"J Clin Oncol"},{"key":"465_CR47","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/bmt.2010.188","volume":"46","author":"WJ Plattel","year":"2011","unstructured":"Plattel WJ, Kluin-Nelemans HC, de Bock GH, et al. Prognostic value of comorbidity for auto-SCT eligibility and outcome in relapsed or refractory aggressive non-Hodgkin\u2019s lymphoma. Bone Marrow Transplant. 2011;46:827\u201334.","journal-title":"Bone Marrow Transplant"},{"key":"465_CR48","doi-asserted-by":"crossref","first-page":"4547","DOI":"10.1002\/cncr.24490","volume":"115","author":"A Tucci","year":"2009","unstructured":"Tucci A, Ferrari S, Bottelli C, et al. A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy. Cancer. 2009;115:4547\u201353.","journal-title":"Cancer"},{"key":"465_CR49","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1200\/JCO.2011.34.7625","volume":"29","author":"A Hurria","year":"2011","unstructured":"Hurria A, Togawa K, Mohile SG, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol. 2011;29:3457\u201365.","journal-title":"J Clin Oncol"},{"key":"465_CR50","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1002\/cncr.26646","volume":"118","author":"M Extermann","year":"2012","unstructured":"Extermann M, Boler I, Reich RR, et al. Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer. 2012;118:3377\u201386.","journal-title":"Cancer"},{"key":"465_CR51","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.2174\/18715206113136660357","volume":"13","author":"L Fratino","year":"2013","unstructured":"Fratino L, Rupolo M, Mazzuccato M, et al. Autologus stem cell transplatation as a care option in elderly patients. A review. Anticancer Agents Med Chem. 2013;13:1419\u201329.","journal-title":"Anticancer Agents Med Chem"},{"key":"465_CR52","first-page":"29","volume":"18","author":"T Demirer","year":"1996","unstructured":"Demirer T, Petersen FB, Bensinger WI, et al. Autologous transplantation with peripheral blood stem cells collected after granulocyte colony-stimulating factor in patients with acute myelogenous leukemia. Bone Marrow Transplant. 1996;18:29\u201334.","journal-title":"Bone Marrow Transplant"},{"key":"465_CR53","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/sj.bmt.1705708","volume":"40","author":"M Tomblyn","year":"2007","unstructured":"Tomblyn M, Burns LJ, Blazar B, et al. Difficult stem cell mobilization despite adequate CD34+ cell dose predicts shortened progression free and overall survival after autologous HSCT for lymphoma. Bone Marrow Transplant. 2007;40:111\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"465_CR54","first-page":"291","volume":"22","author":"EA Stadtmauer","year":"1995","unstructured":"Stadtmauer EA, Schneider CJ, Silberstein LE. Peripheral blood progenitor cell generation and harvesting. Semin Oncol. 1995;22:291\u2013300.","journal-title":"Semin Oncol"},{"key":"465_CR55","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/sj.bmt.1701941","volume":"24","author":"R Kanteti","year":"1999","unstructured":"Kanteti R, Miller K, McCann J, et al. Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin\u2019s lymphoma and Hodgkin\u2019s disease: a clinical and molecular analysis. Bone Marrow Transplant. 1999;24:473\u201381.","journal-title":"Bone Marrow Transplant"},{"key":"465_CR56","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1200\/JCO.2002.09.138","volume":"20","author":"JM Vose","year":"2002","unstructured":"Vose JM, Sharp G, Chan WC, et al. Autologous transplantation for aggressive non-Hodgkin\u2019s lymphoma: results of a randomized trial evaluating graft source and minimal residual disease. J Clin Oncol. 2002;20:2344\u201352.","journal-title":"J Clin Oncol"},{"key":"465_CR57","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/sj.bmt.1704702","volume":"35","author":"U Steidl","year":"2005","unstructured":"Steidl U, Fenk R, Bruns I, et al. Successful transplantation of peripheral blood stem cells mobilized by chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma. Bone Marrow Transplant. 2005;35:33\u20136.","journal-title":"Bone Marrow Transplant"},{"key":"465_CR58","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1537-2995.2006.00699.x","volume":"46","author":"I Bruns","year":"2006","unstructured":"Bruns I, Steidl U, Kronenwett R, et al. A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma. Transfusion. 2006;46:180\u20135.","journal-title":"Transfusion"},{"key":"465_CR59","doi-asserted-by":"crossref","first-page":"405","DOI":"10.3324\/haematol.11287","volume":"93","author":"N Russell","year":"2008","unstructured":"Russell N, Mesters R, Schubert J, et al. A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin\u2019s lymphoma receiving chemotherapy. Haematologica. 2008;93:405\u201312.","journal-title":"Haematologica"},{"key":"465_CR60","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/ajh.23561","volume":"88","author":"IN Micallef","year":"2013","unstructured":"Micallef IN, Stiff PJ, Stadtmauer EA, et al. Safety and efficacy of upfront plerixafor\u2009+\u2009G-CSF versus placebo\u2009+\u2009G-CSF for mobilization of CD34(+) hematopoietic progenitor cells in patients >\/=60 and <60 years of age with non-Hodgkin\u2019s lymphoma or multiple myeloma. Am J Hematol. 2013;88:1017\u201323.","journal-title":"Am J Hematol"},{"key":"465_CR61","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.coi.2014.05.002","volume":"29","author":"H Geiger","year":"2014","unstructured":"Geiger H, Denkinger M, Schirmbeck R. Hematopoietic stem cell aging. Curr Opin Immunol. 2014;29:86\u201392.","journal-title":"Curr Opin Immunol"},{"key":"465_CR62","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00277-009-0812-9","volume":"89","author":"A Tempescul","year":"2010","unstructured":"Tempescul A, Ianotto JC, Hardy E, et al. Peripheral blood stem cell collection in elderly patients. Ann Hematol. 2010;89:317\u201321.","journal-title":"Ann Hematol"},{"key":"465_CR63","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.bbmt.2014.03.001","volume":"20","author":"CM Woolthuis","year":"2014","unstructured":"Woolthuis CM, Mariani N, Verkaik-Schakel RN, et al. Aging impairs long-term hematopoietic regeneration after autologous stem cell transplantation. Biol Blood Marrow Transplant. 2014;20:865\u201371.","journal-title":"Biol Blood Marrow Transplant"},{"key":"465_CR64","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1080\/10428190500235884","volume":"46","author":"LR Mileshkin","year":"2005","unstructured":"Mileshkin LR, Seymour JF, Wolf MM, et al. Cardiovascular toxicity is increased, but manageable, during high-dose chemotherapy and autologous peripheral blood stem cell transplantation for patients aged 60 years and older. Leuk Lymphoma. 2005;46:1575\u20139.","journal-title":"Leuk Lymphoma"},{"key":"465_CR65","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.bbmt.2008.05.002","volume":"14","author":"TM Wildes","year":"2008","unstructured":"Wildes TM, Augustin KM, Sempek D, et al. Comorbidities, not age, impact outcomes in autologous stem cell transplant for relapsed non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2008;14:840\u20136.","journal-title":"Biol Blood Marrow Transplant"},{"key":"465_CR66","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/sj.bmt.1705266","volume":"37","author":"E Jantunen","year":"2006","unstructured":"Jantunen E, Itala M, Juvonen E, et al. Autologous stem cell transplantation in elderly (>60 years) patients with non-Hodgkin\u2019s lymphoma: a nation-wide analysis. Bone Marrow Transplant. 2006;37:367\u201372.","journal-title":"Bone Marrow Transplant"},{"key":"465_CR67","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/bmt.2010.294","volume":"46","author":"N Puig","year":"2011","unstructured":"Puig N, Pintilie M, Seshadri T, et al. High-dose chemotherapy and auto-SCT in elderly patients with Hodgkin\u2019s lymphoma. Bone Marrow Transplant. 2011;46:1339\u201344.","journal-title":"Bone Marrow Transplant"},{"key":"465_CR68","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/00007890-198611000-00015","volume":"42","author":"R Pecego","year":"1986","unstructured":"Pecego R, Hill R, Appelbaum FR, et al. Interstitial pneumonitis following autologous bone marrow transplantation. Transplantation. 1986;42:515\u20137.","journal-title":"Transplantation"},{"key":"465_CR69","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1182\/blood-2002-04-1261","volume":"101","author":"C Metayer","year":"2003","unstructured":"Metayer C, Curtis RE, Vose J, et al. Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case\u2013control study. Blood. 2003;101:2015\u201323.","journal-title":"Blood"},{"key":"465_CR70","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1200\/JCO.1999.17.10.3128","volume":"17","author":"JW Friedberg","year":"1999","unstructured":"Friedberg JW, Neuberg D, Stone RM, et al. Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin\u2019s lymphoma. J Clin Oncol. 1999;17:3128\u201335.","journal-title":"J Clin Oncol"},{"key":"465_CR71","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1080\/10428190500527769","volume":"47","author":"N Puig","year":"2006","unstructured":"Puig N, de la Rubia J, Remigia MJ, et al. Morbidity and transplant-related mortality of CBV and BEAM preparative regimens for patients with lymphoid malignancies undergoing autologous stem-cell transplantation. Leuk Lymphoma. 2006;47:1488\u201394.","journal-title":"Leuk Lymphoma"},{"key":"465_CR72","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.clml.2013.03.009","volume":"13","author":"BM William","year":"2013","unstructured":"William BM, Loberiza Jr FR, Whalen V, et al. Impact of conditioning regimen on outcome of 2-year disease-free survivors of autologous stem cell transplantation for Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk. 2013;13:417\u201323.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"Suppl 1","key":"465_CR73","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1093\/annonc\/9.suppl_1.S15","volume":"9","author":"N Mounier","year":"1998","unstructured":"Mounier N, Gisselbrecht C. Conditioning regimens before transplantation in patients with aggressive non-Hodgkin\u2019s lymphoma. Ann Oncol. 1998;9 Suppl 1:S15\u201321.","journal-title":"Ann Oncol"},{"key":"465_CR74","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/bmt.2008.298","volume":"43","author":"RZ Yusuf","year":"2009","unstructured":"Yusuf RZ, Dey B, Yeap BY, et al. Autologous SCT with a dose-reduced BU and CY regimen in older patients with non-Hodgkin\u2019s lymphoma. Bone Marrow Transplant. 2009;43:37\u201342.","journal-title":"Bone Marrow Transplant"},{"key":"465_CR75","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1200\/JCO.2006.09.1215","volume":"25","author":"AK Gopal","year":"2007","unstructured":"Gopal AK, Rajendran JG, Gooley TA, et al. High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults\u2009>\u2009or\u2009=\u200960 years old with relapsed or refractory B-cell lymphoma. J Clin Oncol. 2007;25:1396\u2013402.","journal-title":"J Clin Oncol"},{"key":"465_CR76","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.bbmt.2014.02.004","volume":"20","author":"AK Gopal","year":"2014","unstructured":"Gopal AK, Gooley TA, Rajendran JG, et al. Myeloablative I-131-tositumomab with escalating doses of fludarabine and autologous hematopoietic transplantation for adults age >\/= 60 years with B cell lymphoma. Biol Blood Marrow Transplant. 2014;20:770\u20135.","journal-title":"Biol Blood Marrow Transplant"},{"key":"465_CR77","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/sj.bmt.1700604","volume":"19","author":"A Stamatoullas","year":"1997","unstructured":"Stamatoullas A, Fruchart C, Khalfallah S, et al. Peripheral blood stem cell transplantation for relapsed or refractory aggressive lymphoma in patients over 60 years of age. Bone Marrow Transplant. 1997;19:31\u20135.","journal-title":"Bone Marrow Transplant"},{"key":"465_CR78","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1038\/sj.bmt.1701272","volume":"21","author":"P Moreau","year":"1998","unstructured":"Moreau P, Milpied N, Voillat L, et al. Peripheral blood stem cell transplantation as front-line therapy in patients aged 61 to 65 years: a pilot study. Bone Marrow Transplant. 1998;21:1193\u20136.","journal-title":"Bone Marrow Transplant"},{"key":"465_CR79","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S1083-8791(00)70044-9","volume":"6","author":"CS Leger","year":"2000","unstructured":"Leger CS, Bredeson C, Kearns B, et al. Autologous blood and marrow transplantation in patients 60 years and older. Biol Blood Marrow Transplant. 2000;6:204\u201310.","journal-title":"Biol Blood Marrow Transplant"},{"key":"465_CR80","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/sj.bmt.1702577","volume":"26","author":"E Jantunen","year":"2000","unstructured":"Jantunen E, Mahlamaki E, Nousiainen T. Feasibility and toxicity of high-dose chemotherapy supported by peripheral blood stem cell transplantation in elderly patients (>\/=60 years) with non-Hodgkin\u2019s lymphoma: comparison with patients <60 years treated within the same protocol. Bone Marrow Transplant. 2000;26:737\u201341.","journal-title":"Bone Marrow Transplant"},{"key":"465_CR81","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/sj.bmt.1702833","volume":"27","author":"AK Gopal","year":"2001","unstructured":"Gopal AK, Gooley TA, Golden JB, et al. Efficacy of high-dose therapy and autologous hematopoietic stem cell transplantation for non-Hodgkin\u2019s lymphoma in adults 60 years of age and older. Bone Marrow Transplant. 2001;27:593\u20139.","journal-title":"Bone Marrow Transplant"},{"key":"465_CR82","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/sj.bmt.1703034","volume":"27","author":"A Olivieri","year":"2001","unstructured":"Olivieri A, Capelli D, Montanari M, et al. Very low toxicity and good quality of life in 48 elderly patients autotransplanted for hematological malignancies: a single center experience. Bone Marrow Transplant. 2001;27:1189\u201395.","journal-title":"Bone Marrow Transplant"},{"key":"465_CR83","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s00277-002-0492-1","volume":"81","author":"F Zallio","year":"2002","unstructured":"Zallio F, Cuttica A, Caracciolo D, et al. Feasibility of peripheral blood progenitor cell mobilization and harvest to support chemotherapy intensification in elderly patients with poor prognosis: non-Hodgkin\u2019s lymphoma. Ann Hematol. 2002;81:448\u201353.","journal-title":"Ann Hematol"},{"key":"465_CR84","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S1083-8791(03)00099-5","volume":"9","author":"JD Bitran","year":"2003","unstructured":"Bitran JD, Klein L, Link D, et al. High-dose myeloablative therapy and autologous peripheral blood progenitor cell transplantation for elderly patients (greater than 65 years of age) with relapsed large cell lymphoma. Biol Blood Marrow Transplant. 2003;9:383\u20138.","journal-title":"Biol Blood Marrow Transplant"},{"key":"465_CR85","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/ajh.10384","volume":"73","author":"M Magagnoli","year":"2003","unstructured":"Magagnoli M, Castagna L, Balzarotti M, et al. Feasibility and toxicity of high-dose therapy (HDT) supported by peripheral blood stem cells in elderly patients with multiple myeloma and non-Hodgkin\u2019s lymphoma: survey from a single institution. Am J Hematol. 2003;73:267\u201372.","journal-title":"Am J Hematol"},{"key":"465_CR86","first-page":"300","volume":"88","author":"L Villela","year":"2003","unstructured":"Villela L, Sureda A, Canals C, et al. Low transplant related mortality in older patients with hematologic malignancies undergoing autologous stem cell transplantation. Haematologica. 2003;88:300\u20135.","journal-title":"Haematologica"},{"key":"465_CR87","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1093\/annonc\/mdm608","volume":"19","author":"C Hosing","year":"2008","unstructured":"Hosing C, Saliba RM, Okoroji GJ, et al. High-dose chemotherapy and autologous hematopoietic progenitor cell transplantation for non-Hodgkin\u2019s lymphoma in patients >65 years of age. Ann Oncol. 2008;19:1166\u201371.","journal-title":"Ann Oncol"},{"key":"465_CR88","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.3324\/haematol.13273","volume":"93","author":"E Jantunen","year":"2008","unstructured":"Jantunen E, Canals C, Rambaldi A, et al. Autologous stem cell transplantation in elderly patients (> or =60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood and Marrow Transplantation registry. Haematologica. 2008;93:1837\u201342.","journal-title":"Haematologica"},{"key":"465_CR89","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/bmt.2010.289","volume":"46","author":"DJ Andorsky","year":"2011","unstructured":"Andorsky DJ, Cohen M, Naeim A, et al. Outcomes of auto-SCT for lymphoma in subjects aged 70 years and over. Bone Marrow Transplant. 2011;46:1219\u201325.","journal-title":"Bone Marrow Transplant"},{"key":"465_CR90","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/ajh.23108","volume":"87","author":"RL Elstrom","year":"2012","unstructured":"Elstrom RL, Martin P, Hurtado Rua S, et al. Autologous stem cell transplant is feasible in very elderly patients with lymphoma and limited comorbidity. Am J Hematol. 2012;87:433\u20135.","journal-title":"Am J Hematol"},{"key":"465_CR91","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/annonc\/mdr035","volume":"23","author":"E Jantunen","year":"2012","unstructured":"Jantunen E, Canals C, Attal M, et al. Autologous stem-cell transplantation in patients with mantle cell lymphoma beyond 65 years of age: a study from the European Group for Blood and Marrow Transplantation (EBMT). Ann Oncol. 2012;23:166\u201371. A large study from European Registry analysing transplant outcomes in elderly patients.","journal-title":"Ann Oncol"},{"key":"465_CR92","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.bbmt.2014.01.025","volume":"20","author":"D Chihara","year":"2014","unstructured":"Chihara D, Izutsu K, Kondo E, et al. High-dose chemotherapy with autologous stem cell transplantation for elderly patients with relapsed\/refractory diffuse large B cell lymphoma: a nationwide retrospective study. Biol Blood Marrow Transplant. 2014;20:684\u20139. A large study of Japanese Transplant Registry on outcomes of autologous transplant in elderly patients with lymphoma.","journal-title":"Biol Blood Marrow Transplant"},{"key":"465_CR93","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1016\/j.bbmt.2014.08.019","volume":"20","author":"PB Dahi","year":"2014","unstructured":"Dahi PB, Tamari R, Devlin SM, et al. Favorable outcomes in elderly patients undergoing high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2014;20:2004\u20139. A large single center study showing feasibility of transplant in select elderly population.","journal-title":"Biol Blood Marrow Transplant"},{"key":"465_CR94","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.clml.2014.07.017","volume":"15","author":"Z Frosch","year":"2015","unstructured":"Frosch Z, Luskin MR, Landsburg DJ, et al. R-CHOP or R-HyperCVAD with or without autologous stem cell transplantation for older patients with mantle cell lymphoma. Clin Lymphoma Myeloma Leuk. 2015;15:92\u20137.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"465_CR95","doi-asserted-by":"crossref","unstructured":"Martin N, Borchiellini D, Coso D, et al. High-dose chemotherapy with carmustine, etoposide, cytarabine and melphalan followed by autologous stem cell transplant is an effective treatment for elderly patients with poor-prognosis lymphoma. Leuk Lymphoma 2015:1\u20139.","DOI":"10.3109\/10428194.2014.1001987"},{"key":"465_CR96","first-page":"981","volume":"14","author":"JW Sweetenham","year":"1994","unstructured":"Sweetenham JW, Pearce R, Philip T, et al. High-dose therapy and autologous bone marrow transplantation for intermediate and high grade non-Hodgkin\u2019s lymphoma in patients aged 55 years and over: results from the European Group for Bone Marrow Transplantation. The EBMT Lymphoma Working Party. Bone Marrow Transplant. 1994;14:981\u20137.","journal-title":"Bone Marrow Transplant"},{"key":"465_CR97","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1200\/JCO.1996.14.4.1327","volume":"14","author":"CB Miller","year":"1996","unstructured":"Miller CB, Piantadosi S, Vogelsang GB, et al. Impact of age on outcome of patients with cancer undergoing autologous bone marrow transplant. J Clin Oncol. 1996;14:1327\u201332.","journal-title":"J Clin Oncol"},{"key":"465_CR98","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1200\/JCO.1997.15.1.18","volume":"15","author":"CR Kusnierz-Glaz","year":"1997","unstructured":"Kusnierz-Glaz CR, Schlegel PG, Wong RM, et al. Influence of age on the outcome of 500 autologous bone marrow transplant procedures for hematologic malignancies. J Clin Oncol. 1997;15:18\u201325.","journal-title":"J Clin Oncol"},{"key":"465_CR99","doi-asserted-by":"crossref","first-page":"128","DOI":"10.6004\/jnccn.2014.0010","volume":"12","author":"TM Wildes","year":"2014","unstructured":"Wildes TM, Stirewalt DL, Medeiros B, et al. Hematopoietic stem cell transplantation for hematologic malignancies in older adults: geriatric principles in the transplant clinic. J Natl Compr Canc Netw. 2014;12:128\u201336. A comprehensive review of autologous and allogeneic stem cell transplant in elderly.","journal-title":"J Natl Compr Canc Netw"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-015-0465-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11912-015-0465-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-015-0465-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T03:44:00Z","timestamp":1717991040000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11912-015-0465-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,23]]},"references-count":99,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["465"],"URL":"https:\/\/doi.org\/10.1007\/s11912-015-0465-x","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,23]]},"article-number":"42"}}